Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00509795 · ClinicalTrials.gov registry record · Phase 3
Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)
A Phase 3 study of Macular Degeneration, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,217
- Enrollment target
- 20
- Study locations
NCT00509795: Completed Phase 3 study of Macular Degeneration, sponsored by Regeneron Pharmaceuticals.
NCT00509795 is a Phase 3 study of Macular Degeneration that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 1,217 participants, above the 132-participant average among 26 other Macular Degeneration trials with a reported enrollment target (822% higher). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00509795, a Phase 3 study of Macular Degeneration, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,217 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is a phase 3, double-masked, randomized, study of the efficacy and safety of VEGF Trap-Eye in patients with neovascular age-related macular degeneration. Approximately 1200 patients will be randomized in the US and Canada.
Primary Outcome
Defined "maintenance of vision" as patients who lost fewer than 15 letters in Early Treatment Diabetic Retinopathy Study (ETDRS) letter score compared to baseline.
Conditions Studied
Interventions
- BIOLOGICAL ranibizumab
- BIOLOGICAL aflibercept injection (VEGF Trap-Eye, BAY86-5321)
Study Locations (20)
California
- - Beverly Hills
- - Campbell
- - Fullerton
- - Glendale
- - Irvine
- - La Jolla
- - Loma Linda
- - Los Angeles
- - Los Angeles
- - Menlo Park
- - Mountain View
- - Oakland
- - Palm Springs
- - Pasadena
Arizona
- - Phoenix
- - Phoenix
- - Tucson
- - Tucson
Alabama
- - Birmingham
- - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,217 participants |
| Start Date | 2007-08 |
| Est. Completion | 2011-07 |
| Phase | Phase 3 |
What the finished NCT00509795 record still lists
NCT00509795 is an interventional study that assigns participants to a tested intervention. Its 1,217 participants enrollment target places it among the larger protocols in the corpus, above the 132-participant average among 26 other Macular Degeneration trials with a reported enrollment target (822% higher).
The record links to 1 condition, with Macular Degeneration appearing as the primary indexed condition, and to 2 interventions - of which ranibizumab is the first listed.
NCT00509795 names 20 study sites across 3 states, led by California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT00509795 about?
NCT00509795 is a clinical study titled "Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)". This study is a phase 3, double-masked, randomized, study of the efficacy and safety of VEGF Trap-Eye in patients with neovascular age-related macular degeneration. Approximately 1200 patients will be randomized in the US and Canada.
What is the current status of trial NCT00509795?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,217 participants. The study started on 2007-08. Estimated completion is 2011-07.
What conditions does trial NCT00509795 study?
This clinical trial studies the following conditions: Macular Degeneration.
What interventions are being tested in trial NCT00509795?
The interventions under investigation include: ranibizumab (BIOLOGICAL), aflibercept injection (VEGF Trap-Eye, BAY86-5321) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00509795?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00509795 being conducted?
This trial has 20 study locations across Alabama, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00509795's enrollment target sits among peer trials
1,217 1st of 26 higher than 26 of 26 other Macular Degeneration trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Macular Degeneration trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD
COMPLETED · Phase 3
-
A Study of Genetic and Environmental Factors and Their Effect on Response to Treatment With Lucentis (Ranibizumab) for Wet AMD
COMPLETED · Phase 3
-
An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMD
COMPLETED · Phase 3
-
Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration (AMD)
COMPLETED · Phase 3
-
Triamcinolone Acetonide Plus Laser Therapy to Treat Age-Related Macular Degeneration
COMPLETED · Phase 3
-
Factors in Learning And Plasticity: Macular Degeneration
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06143956 · 1,217 participants · Phase 2
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- NCT05827016 · 1,216 participants · Phase 3
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
- NCT06921785 · 1,220 participants · Phase 3
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
- NCT04267848 · 1,210 participants · Phase 3
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia